ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) and Opus Genetics (NASDAQ:IRD – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends and risk.
Insider and Institutional Ownership
32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 11.7% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares ProQR Therapeutics and Opus Genetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProQR Therapeutics | -223.51% | -73.83% | -35.14% |
| Opus Genetics | -1,091.82% | -338.88% | -150.13% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProQR Therapeutics | $17.99 million | 9.66 | -$47.73 million | ($0.46) | -3.59 |
| Opus Genetics | $14.20 million | 27.71 | -$49.59 million | ($1.35) | -3.53 |
ProQR Therapeutics has higher revenue and earnings than Opus Genetics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
ProQR Therapeutics has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and price targets for ProQR Therapeutics and Opus Genetics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProQR Therapeutics | 1 | 1 | 6 | 0 | 2.62 |
| Opus Genetics | 1 | 1 | 15 | 1 | 2.89 |
ProQR Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 354.55%. Opus Genetics has a consensus target price of $11.92, indicating a potential upside of 150.48%. Given ProQR Therapeutics’ higher probable upside, equities research analysts plainly believe ProQR Therapeutics is more favorable than Opus Genetics.
Summary
ProQR Therapeutics beats Opus Genetics on 8 of the 15 factors compared between the two stocks.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
About Opus Genetics
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
